The ISSCR Comments on the MHRA Consultation on Point of Care Manufacturing

  • 23 September, 2021
News from ISSCR website tile The ISSCR submitted comments to the UK's MHRA on the Consultation on Point of Care Manufacturing that state, among other key points:  We are particularly concerned that purveyors of autologous adipose-derived cell therapies might seek to exploit the regulations to sell adipose-derived cells for indications that they have not been shown to treat effectively. These therapies and all ATMPs should be preceded by well-regulated trials and testing that demonstrate the safety, efficacy, and quality of such products.

Read the comments.